Skip to main content
OpenTrials
Completed

NCT Number: NCT02316665

Effect of Sleep Apnea Treatment on Type 1 Diabetes

Hypothesis: To address the role of continuous positive airway pressure (CPAP)on nocturnal glycemia in patients having type 1 diabetes and sleep apnea syndrome.

Investigators make the hypothesis that sleep apnea syndrome impacts nocturnal glycemia in type 1 diabetic patients and that continuous positive airway pressure treatment will permit to improve the nocturnal glycemic profile.

Study design: Adult patients with type 1 diabetes will be recruited for an extensive study of sleep habits and assessment of sleep breathing disorders. When patients will present with severe sleep apnea syndrome (apnea-hypopnea index above 30 events/hour) and insufficient glycemic control (HbA1c > 7.5%), they will be randomized in continuous positive airway pressure treatment or sham-continuous positive airway pressure treatment group for three months.

Main outcome: Nocturnal glycemic control will be assessed for 5 days before and after three months of the allocated treatment.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Quality of clinical study procedures will be checked by on-site audit.

Patient self-reported past medical history will be checked by reviewing medical records.

Paper case report forms will be used.

For the baseline extensive study of sleep habits, the following data are recorded:

  • Self-reported sleep diary (7 days)
  • Actimetric device (7 days)
  • Munich Chronotype Questionnaire
  • 24h-dietary recall
  • Salivary collections every 30 minutes between 7:30 pm and 22:00 pm on one night to address the dim light melatonin onset.
  • Other questionnaires: Job strain questionnaire, EPICES (precarity questionnaire) and DQOL (diabetes related quality of life)
  • Nocturnal oxymetry

Blood measurements: HbA1c, lipidic profile, microalbuminuria, creatinin

After baseline assessment, patients having an abnormal nocturnal oximetry will be explored by polysomnography in order to detect a sleep apnea syndrome.

Investigators anticipate, based on a previous pilot study of our group ("Borel" Diab Med 2010), that 30% of screened patients will present with sleep apnea.

If patients present with severe sleep apnea (IAH > 30 events/hour) and HbA1c > 7.5%, they will be randomized for the intervention.

Sample size: based on a previous study by "Pallayova" et al. in patients having type 2 diabetes, investigators anticipate a difference between groups of 1.3 (SD 2.07) for the mean nocturnal glycemia. For a alpha threshold of 5% and a study power of 80%, the study should include 32 patients in each group. Taking in account a possible 25% of dropout the study will need to include 40 patients by randomized arm to demonstrate an effect.

Statistical analysis: An intention-to-treat analysis will be performed. Missing data for the continuous positive airway pressure group will be replaced by the median value at three-month of the sham-continuous positive airway pressure group and reciprocally.

In a second analysis, a per-protocol analysis will be performed limited to patients having completed their treatment in allocated group and having an adherence to continuous positive airway pressure or sham-continuous positive airway pressure treatment for more than 4-hours a night.

Normality of data will be checked by Kurtosis and Skewness tests. The significance level will be set at 5%.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients with type 1 diabetes

Exclusion criteria

  • Pregnant women
  • Patient with acute metabolic disorders during the past three months
  • Shift workers
  • Institutionalized patient
  • Enteral and parenteral nutrition

Treatment and study plan

Continuous Positive Airway Pressure

Device

continuous positive airway pressure treatment during three months with adherence recording

Sham-continuous positive airway pressure

Device

Sham-continuous positive airway pressure during three months with adherence recording

Primary outcomes

  1. change in mean nocturnal glycemia

    Time frame: 3 months

    Measured from continuous glycemic monitoring system

Secondary outcomes

  1. Change in blood pressure

    Time frame: 3 months

    24h ambulatory blood pressure monitoring

  2. Change in the variability of nocturnal glycemia

    Time frame: 3months

    Measured on nighttime recording of continuous glycemic monitoring system

  3. Change in HbA1c

    Time frame: 3 months

  4. Changes in sleep duration after intervention

    Time frame: 3 months

    Actimetry

  5. Change in mean systolic blood pressure after intervention

    Time frame: 3 months

    Self-monitoring blood pressure and heart rate device, at home

  6. Chang in sleep timing after intervention

    Time frame: 3 months

    Actimetry

  7. Change in daily activity after intervention

    Time frame: 3 months

    Actimetry

  8. Change in mean diastolic blood pressure after intervention

    Time frame: 3 months

    Self-monitoring blood pressure and heart rate device, at home

  9. Change in mean heart rate after intervention

    Time frame: 3 months

    Self-monitoring blood pressure and heart rate device, at home

Sponsors and collaborators

Lead sponsor

University Hospital, Grenoble

Other

Collaborators

  • ResMed
  • Société francophone de pneumologie de langue francaise

Registry information

Official study title

Effect of Continuous Positive Airway Pressure Treatment on Nocturnal Glycemia of Patients Having Type 1 Diabetes and Sleep Apnea Syndrome: a Randomized Controlled Trial

Acronym: DIADEME

Important dates

Study start
2013
Primary completion
2014
Study completion
2015
First posted
Dec 15, 2014
Registry last updated
Jan 6, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.